| Literature DB >> 35189927 |
Delphine Genevaz1, Armelle Arnoux2, Catherine Marcel3, Anaïs Brassier4, Samia Pichard4, François Feillet5, François Labarthe6, Brigitte Chabrol7, Marc Berger8, Anne-Sophie Lapointe1, Yvann Frigout2, Bénédicte Héron9, Gilles Chatellier2, Nadia Belmatoug10.
Abstract
BACKGROUND: Transition from childhood to adulthood (TCA) is usually difficult in rare, progressive and multisystemic diseases. New treatments and modalities of care for many lysosomal diseases (LD) can increase life expectancy, and a successful TCA can help patient who reach adulthood to avoid disruption to health care. In France, some TCA initiatives have been taken by referral centers but in view of the problems encountered by Vaincre les Maladies Lysosomales (VML), the LD patient association, they seem to be insufficient. The aim of this study is to determine the current state of the TCA process and to identify actions to improve it through interviews with patient families and physicians in LD referral centers. The study is based upon an observational, non-interventional, cross-sectional, national survey which used two anonymous questionnaires. These questionnaires, developed by a scientific committee including representatives from VML and medical specialists in LD, were sent to patients who were receiving care in pediatric departments at age 15 years or older. Questionnaires were also sent to their referral pediatricians.Entities:
Keywords: Lysosomal diseases; Patient opinion; Patient survey; Transition from childhood to adulthood
Mesh:
Year: 2022 PMID: 35189927 PMCID: PMC8862388 DOI: 10.1186/s13023-022-02232-w
Source DB: PubMed Journal: Orphanet J Rare Dis ISSN: 1750-1172 Impact factor: 4.123
Characteristics of patients monitored in a pediatric department
| Characteristics | Patients | Patients | Patients |
|---|---|---|---|
| Gender, male n (%) | 34/54 (63.0%) | 23/41 (56.1%) | 11/13 (84.6%) |
| Disease | |||
| Mucopolysaccharidosis | 35/53 (66.0%) | 25/41 (61.0%) | 10/12 (83.4%) |
| Gaucher type 1 | 6/53 (11.3%) | 5/41 (12.2%) | 1/12 (8.3%) |
| Alpha mannosidosis | 3/53 (5.7%) | 3/41 (7.3%) | – |
| Fucosidosis | 2/53 (3.8%) | 2/41 (4.9%) | – |
| Metachromatic leukodystrophy | 2/53 (3.8%) | 1/41 (2.4%) | 1/12 (8.3%) |
| Others (Fabry, gangliosidosis, Danon, cholesteryl ester storage disease, Niemann-Pick type B: n = 1 each) | 5/53 (9.4%) | 5/41 (12.2%) | – |
| Other patient characteristics | |||
| Chronic pain | 18/52 (34.6%) | 14/40 (35.0%) | 4/12 (33.3%) |
| Orthosis need | 8/51 (15.7%) | 8/39 (20.5%) | 0/12 (0.0%) |
| Mechanical respiratory | 12/53 (22.6%) | 10/40 (25.0%) | 2/13 (15.4%) |
| Mobility assistance | 23/54 (42.9%) | 20/41 (48.8%) | 3/13 (23.1%) |
| Disability* | 40/54 (74.1%) | 30/41 (73.2%) | 10/13 (76.9%) |
| Hospitalization or surgery in the last 6 months or planned in the next 12 months | 14/54 (25.9%) | 13/41 (31.7%) | 1/13 (7.7%) |
| Treatment by/for | |||
| Enzyme replacement therapy | 34/53 (64.1%) | 25/41 (61.0%) | 9/12 (75.0%) |
| Epilepsy | 10/54 (18.5%) | 9/41 (21.9%) | 1/13 (7.7%) |
| Sleeping disorders | 4/54 (7.4%) | 4/41 (9.7%) | 0/13 (0.0%) |
| Spasticity | 2/54 (3.7%) | 1/41 (2.4%) | 1/13 (7.7%) |
| Tremor | 2/54 (3.7%) | 2/41 (4.8%) | 0/13 (0.0%) |
| Transplantation: | 9/53 (17.0%) | 7/40 (17.5%) | 2/13 (15.4%) |
| Heart | 1/9 (11.1%) | 1/7 (14.3%) | 0/2 (0.0%) |
| Bone marrow | 8/9 (88.9%) | 6/7 (85.7%) | 2/2 (100.0%) |
*Difficulty with at least one of the following: hearing/sight/speech/writing/attention/memory/learning/comprehension
Fig. 1A Patient’s responses on proposed actions and priorities for TCA, B Physicians’ responses on priorities for TCA